Clay Siegall Leads Seattle Genetics on a Growth Trajectory Path to Help Investors

Home / Clay Siegall Leads Seattle Genetics on a Growth Trajectory Path to Help Investors

Seattle Genetics is one of the leading biotech companies with its headquarters at Bothell Cascade Business Park. The giant biotech company is located in a seemingly quiet area, with no major scientific sophistications on the outside. In fact, as you head towards the headquarters, you will hardly believe if there could be a giant biotech company in that location. But as you get inside to the third building, there is a huge green triangular sculpture that looks like it is made of Lego bricks. The triangular sculpture is a simplified model of a human antibody.

The massive sculpture is enough to alert even a stranger of what goes on behind the closed doors. Since its foundation in 1998, Seattle Genetics has focused all its energy on studying, researching, manipulating human antibodies with the aim of producing drugs that will help individuals to fight various ailments. The antibodies manufactured by Seattle Genetics contribute to delivering a toxic payload into a cancer cell, which contributes to destroying it from the inside. They are considered effective when they are used together with the appropriate therapies.

Seattle Genetics conducts its business entirely different as compared to other biotech companies. That is one thing that will help the company to play in the big leagues. The company has huge ambitions of becoming the largest and the most efficient biotech company both locally and internationally. Seattle Genetics currently boasts of having a market value that has hit the $10 billion mark and with close to one thousand employees on its payroll. The company hopes to soon graduate from a biotech firm that it is today to a huge pharmaceutical company.

The company has invested largely in research as they strive to bring more innovative ideas and products to the market. Seattle Genetics has also been involved in aggressive marketing to bring more customers aboard. As part of its growth strategy, Seattle Genetics expects to add more talent to its pool as they seek to hire some more 200 employees this year.

In 2016, the firm is reported to have collected a whopping $418 million, which is 46 percent up from what it received in 2014. Seattleā€™s stock price has shot from $20 a share to $66, which is a triple factor. Although Seattle Genetics is yet to record profit, the recent growth trajectory is very promising to investors and the general public.

About Clay Siegall

Dr. Clay Siegall is the co-founder of Seattle Genetics. He co-founded the firm 18 years ago, and he currently serves as the President, the CEO and Chairman of the Board. Clay Siegall is a trained scientist with a focus on targeted cancer therapies. Dr. Siegall built Seattle Genetics on a firm ground of research, innovation, and drug production practices that have catapulted the organization to its current status.